-
Beckley Psytech Begins Phase IIa Study Of Psychedelic Compound To Treat Depression
Thursday, May 4, 2023 - 4:37pm | 341Clinical-stage private biotech company Beckley Psytech Ltd announced that the first patient has been dosed in their Phase IIa study of BPL-003, a synthetic formulation of the psychedelic compound 5-MeO-DMT, for Treatment-Resistant Depression (TRD). Dr. Rob Conley, chief scientific officer at...